CN102276623A - Novel method of preparing prasugrel with organosilicon protectant - Google Patents
Novel method of preparing prasugrel with organosilicon protectant Download PDFInfo
- Publication number
- CN102276623A CN102276623A CN2011101577402A CN201110157740A CN102276623A CN 102276623 A CN102276623 A CN 102276623A CN 2011101577402 A CN2011101577402 A CN 2011101577402A CN 201110157740 A CN201110157740 A CN 201110157740A CN 102276623 A CN102276623 A CN 102276623A
- Authority
- CN
- China
- Prior art keywords
- pra
- prasugrel
- reaction
- pyridine
- triethylamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- DTGLZDAWLRGWQN-UHFFFAOYSA-N prasugrel Chemical compound C1CC=2SC(OC(=O)C)=CC=2CN1C(C=1C(=CC=CC=1)F)C(=O)C1CC1 DTGLZDAWLRGWQN-UHFFFAOYSA-N 0.000 title claims abstract description 23
- 239000005465 B01AC22 - Prasugrel Substances 0.000 title claims abstract description 22
- 229960004197 prasugrel Drugs 0.000 title claims abstract description 22
- 238000000034 method Methods 0.000 title claims abstract description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims abstract description 57
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims abstract description 38
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims abstract description 23
- 238000006243 chemical reaction Methods 0.000 claims abstract description 22
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims abstract description 19
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims abstract description 16
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims abstract description 16
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000002904 solvent Substances 0.000 claims abstract description 9
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims abstract description 8
- 238000005917 acylation reaction Methods 0.000 claims abstract description 6
- 230000010933 acylation Effects 0.000 claims abstract description 3
- 239000003054 catalyst Substances 0.000 claims abstract description 3
- 238000006482 condensation reaction Methods 0.000 claims abstract description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 3
- 150000007530 organic bases Chemical class 0.000 claims abstract description 3
- 238000006277 sulfonation reaction Methods 0.000 claims abstract description 3
- 238000002360 preparation method Methods 0.000 claims description 17
- ZQFIAAFKCPCOQZ-UHFFFAOYSA-N 2-chloro-2,3-dimethylbutane silane Chemical compound [SiH4].CC(C(C)(C)Cl)C ZQFIAAFKCPCOQZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 230000001681 protective effect Effects 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- -1 organosilyl ketone compound Chemical class 0.000 claims description 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 5
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 claims description 4
- 229960003328 benzoyl peroxide Drugs 0.000 claims description 3
- TXNUWPJKALQINZ-UHFFFAOYSA-N 1-[2-bromo-2-(2-fluorophenyl)cyclopropyl]propan-1-one Chemical compound C(C)C(=O)C1C(C1)(C1=C(C=CC=C1)F)Br TXNUWPJKALQINZ-UHFFFAOYSA-N 0.000 claims description 2
- 150000002576 ketones Chemical class 0.000 claims description 2
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 claims description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 2
- 239000007787 solid Substances 0.000 abstract description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 abstract description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 abstract description 9
- 239000002994 raw material Substances 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 239000011230 binding agent Substances 0.000 abstract 2
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 abstract 1
- 231100000086 high toxicity Toxicity 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 abstract 1
- 238000003756 stirring Methods 0.000 description 28
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 238000013016 damping Methods 0.000 description 11
- 239000012530 fluid Substances 0.000 description 11
- 238000005406 washing Methods 0.000 description 10
- 239000002585 base Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 239000011259 mixed solution Substances 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 238000001035 drying Methods 0.000 description 6
- 238000001914 filtration Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 229940127218 antiplatelet drug Drugs 0.000 description 3
- 229960003009 clopidogrel Drugs 0.000 description 3
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 150000003222 pyridines Chemical class 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 2
- 101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 description 2
- 101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- KAVSMINTEBGDTI-UHFFFAOYSA-N pyridine;thiophene Chemical class C=1C=CSC=1.C1=CC=NC=C1 KAVSMINTEBGDTI-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical group OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960005001 ticlopidine Drugs 0.000 description 2
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- QLUBZVMQZRMXCK-UHFFFAOYSA-N ClC1=NC=CC=C1.S1C=CC=C1 Chemical compound ClC1=NC=CC=C1.S1C=CC=C1 QLUBZVMQZRMXCK-UHFFFAOYSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- QSMTUAJDOTXEDZ-UHFFFAOYSA-N N1C=CC=C1.[Cl] Chemical compound N1C=CC=C1.[Cl] QSMTUAJDOTXEDZ-UHFFFAOYSA-N 0.000 description 1
- 102000010888 P2Y12 purinoceptor Human genes 0.000 description 1
- 108010014270 Purinergic P2Y12 Receptors Proteins 0.000 description 1
- JALHGCPDPSNJNY-UHFFFAOYSA-N [5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-6,7-dihydro-4h-thieno[3,2-c]pyridin-2-yl] acetate;hydron;chloride Chemical compound Cl.C1CC=2SC(OC(=O)C)=CC=2CN1C(C=1C(=CC=CC=1)F)C(=O)C1CC1 JALHGCPDPSNJNY-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013176 antiplatelet therapy Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000006757 chemical reactions by type Methods 0.000 description 1
- 229960004588 cilostazol Drugs 0.000 description 1
- RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229950003837 ozagrel Drugs 0.000 description 1
- SHZKQBHERIJWAO-AATRIKPKSA-N ozagrel Chemical compound C1=CC(/C=C/C(=O)O)=CC=C1CN1C=NC=C1 SHZKQBHERIJWAO-AATRIKPKSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000011020 pilot scale process Methods 0.000 description 1
- 229960004947 prasugrel hydrochloride Drugs 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 208000009363 superior mesenteric artery syndrome Diseases 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical class C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- DBDCNCCRPKTRSD-UHFFFAOYSA-N thieno[3,2-b]pyridine Chemical compound C1=CC=C2SC=CC2=N1 DBDCNCCRPKTRSD-UHFFFAOYSA-N 0.000 description 1
- 229940125670 thienopyridine Drugs 0.000 description 1
- 239000002175 thienopyridine Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The invention discloses a novel method of preparing prasugrel with a organosilicon protectant, relating to the chemical synthesis of prasugrel, comprising the following steps: letting PRA-3 and toluenesulfonic acid be subject to sulfonation reaction in the presence of tetrahydrofuran as a solvent at the temperature of 45-75 DEG C to generate PRA-4B; then letting PRA-4B react with tert-butyldimethylsilyl chloride in the presence of dichloromethane as a solvent at the temperature of -5-10 DEG C to protect the hydroxyl in the intermediate, and then letting PRA-4B and PRA-7 be subject to condensation reaction in the presence of organic base as a binding agent at the temperature of -5-10 DEG C to generate PRA-5B; and finally, letting PRA-5B and acetic anhydride be subject to acylation reaction in the presence of tetrahydrofuran as a solvent, triethylamine or pyridine as a binding agent, and 4-dimethylamino-pyridine as an acylation catalyst, at normal temperature to generate PRA-6B, that is, prasugrel. The beneficial effects of the invention are that: the whole reaction process is completed by only three steps without using NaH, toluene, methanol and other raw materials which has bad security, strong corrosivity and high toxicity, and is very mild and easy to control, and the products of the three steps are solids, the post-treatment is simple, the product yield is high, and the purity is high. The method is easy to apply in industry.
Description
Technical field
The present invention relates to the chemosynthesis of prasugrel, specifically is a kind of novel method of utilizing the organosilicon protective material to be prepared prasugrel.
Background technology
Prasugrel is thiophene chloropyridine, chlorine pyrrole thunder lattice analogue, English Prasugrel by name, be called for short PRA, chemical name: 2-acetoxyl group-5-(α-cyclopropyl carbonyl-2-luorobenzyl)-4,5,6, the 7-tetramethylene sulfide is [3,2-c] pyridine also, by Japan three altogether, the P2Y12 purinoceptor antagonist with oral property of Ube Industries, the common exploitation of Lilly, be the lead compound in a series of tetramethylene sulfides and the pyridine derivatives, structural formula is
As platelet aggregation inhibitor, with prevention and treatment thrombosis.
This medicine original chemical patent is that Japanese Sankyo Co., Ltd " contains the preparation method of hydrogenation pyridine derivate as the medicinal compositions of its activeconstituents " and (writes by the process for preparing medicine patent; application number 98109220.9; 2012.9.8 expire), this patent protection the prasugrel free alkali.The substance patent of mandate " hydrogenated pyridine derivative as one kind of acid added salt " (01815108.6 of the prasugrel pharmacologically acceptable salt of the said firm's application simultaneously; 2021.7.2 expire) to prasugrel hydrochloride having and maleate, and the conventional formulation that contains them is protected.
Shandong University has applied for the patent " prasugrel salt and preparation method thereof " (200810014873.2, substantive examination) of this medicine desalination hydrochlorate and outer other pharmacologically acceptable salt commonly used of maleate, but for want of creative mandate prospect is little.
The patent of preparation method aspect comprises " a kind of medicine intermediate and preparation method thereof " (200810034996.2 of Shanghai medical professionals institute application, substantive examination), " intermediate of preparation prasugrel and preparation method thereof " (200810034995.8, substantive examination), " 5-(α-cyclopropyl carbonyl-2-luorobenzyl)-2-oxygen-2; 4; 5; 6,7, the preparation method of 7a-six hydrogen thieno-s [3; 2-c] pyridine " (200810035041.9, substantive examination), " preparation method of hydrogenated pyridine derivative and salt thereof " (200710195018.1, deemed withdrawal) of Shandong southern Shandong pharmaceutical applications.
The preparation aspect, the conventional formulation of having protected in the aforementioned substances patent, the patent of Lilly Co., Eli. " thienopyridine platelet aggregation inhibitor preparation " (200680020528.9, substantive examination) protected a kind of packing and dosage of solid preparation.Gift comes company also to apply for dosage regimen for prasugrel patent (200680021794.3, substantive examination) in addition.
In recent years, along with the aging day by day of China's population, vascular thrombosis plug morbidity is soaring year by year, on the market demand of prevention and treatment thrombotic diseases medicine is presented the gesture of growth year by year.
And antiplatelet drug mainly is salicylic acid, thiophene pyridines (Ticlopidine, clopidogrel) and glycoprotein iib/iiia antagonist.The platelet aggregation-against class medicine of China's clinical application comprises clopidogrel, ozagrel, Cilostazole, acetylsalicylic acid, Ticlopidine and Dipyridamole, and market presents the feature of high concentration.The standard Antiplatelet therapy scheme that acetylsalicylic acid and a kind of thiophene pyridine drug combination are present acute superior mesenteric artery syndromes.Weak point is that about 20% patient has non-responsiveness to clopidogrel, and drug combination can not reduce this type of patient's ischemic conditions, and simultaneously individual difference is big, onset slow, untoward reaction and acetylsalicylic acid are approaching.
Simultaneously, the inventor understands in numerous documents, and the prasugrel synthetic route has all related to 2 important intermediate, 2-fluoro-α-ring propionyl bromobenzyl and 2-carbonyl-2,4,5,6,7,7 α-six hydrogen thieno-[3,2-c] pyridine hydrochloride, its reaction rules commonly used are summarized as follows:
First intermediate
Second intermediate
Alignment analysis: reaction type is a popular response, does not have obvious severe condition restriction, and yield is general.Difficult point is to obtain 1,3 starting raw materials, also can synthesize starting raw material, and according to present domestic synthetic result, the synthetic difficulty of this product can not become the bottleneck of exploitation.
In sum; this medicine hyle patent is near the phase, but the patent of its hydrochloride and maleate also has patent protection period for a long time, if this medicine of exploitation; need avoid its hydrochloride and maleate, and the patent of avoiding other preparation method and preparation aspect.
Summary of the invention
Technical problem solved by the invention is to provide strong toxicities such as a kind of NaH of avoiding, toluene, methyl alcohol, corrodibility rough property supplementary material strong, poor stability to prepare the method for prasugrel; adopt the mildness supplementary material, and reactions steps reduces, process shortens, operation utilizes the organosilicon protective material to be prepared the novel method of prasugrel easily.
Technical problem solved by the invention realizes by the following technical solutions:
A kind of novel method of utilizing the organosilicon protective material to be prepared prasugrel is characterized in that may further comprise the steps:
A, at first make solvent at tetrahydrofuran (THF), carry out the sulfonate PRA-4B that sulfonation reaction generates corresponding ketone with tosic acid under 45 ℃～75 ℃ the condition by PRA-3 (5,6,7,7A-tetrahydrochysene-5-(trityl) thieno-[3,2-c] pyridone);
B, the PRA-4B that obtains by step a make solvent at methylene dichloride, triethylamine is done the constraint agent, generates organosilyl ketone compound PRA-5B with 2-bromo-2-(2-fluorophenyl)-1-cyclopropyl ethyl ketone (PRA-7) generation condensation reaction again under-5 ℃～10 ℃ and do constraint agent conditions such as organic bases such as triethylamine, pyridine after with dimethyl tertiary butyl chloride silane reaction the hydroxyl in the intermediate being protected under-5 ℃～10 ℃ conditions;
C, last organosilyl ketone compound PRA-5B do solvent, triethylamine or pyridine do constraint agent at tetrahydrofuran (THF), the 4-Dimethylamino pyridine is made acylation catalyst; normal temperature condition descends and aceticanhydride generation acylation reaction finally generates target product PRA-6B; PRA-9-prasugrel-the 2-[2-(acetoxyl group)-6 of reaction rules promptly commonly used preparation; the 7-dihydro-thiophene is [3,2-c] pyridines-5 (4H)-yl also]-1-cyclopropyl-2-(2-fluorophenyl) ethyl ketone.
In the present invention, described PRA-3 is prepared from by following process
Described organosilicon protective material is a dimethyl tertiary butyl chloride silane.
The beneficial effect that has in the present invention is that entire reaction course only had only for three steps, do not use poor stability such as NaH, toluene, methyl alcohol, corrodibility is strong, toxicity is big supplementary material in the reaction process, process is easy to control as mild as a dove, and the product of three-step reaction all is a solids, aftertreatment is simple, product yield height, purity height are easy to suitability for industrialized production.Transformation efficiency of product reaches (traditional technology is up to 85%) more than 92%; Also improved labour productivity on the other hand, reduced the consumption of supplementary material, also reduced production cost (having reduced more than 5%) than traditional technology; Working condition is gentle friendly simultaneously, facility simple to operate.
Embodiment
For technique means, creation characteristic that the present invention is realized, reach purpose and effect is easy to understand, below by specific embodiment, further set forth the present invention.
A kind of novel method of utilizing the organosilicon protective material to be prepared prasugrel, its reaction rules are as follows:
At first PRA-3 is prepared from by following process
Secondly, in reactor, add tosic acid, THF, stirring and dissolving; Add PRA-3 then, interior temperature refluxed 2 hours for 64 ℃, and cooling has solids to separate out naturally, and filtering drying gets PRA-4B;
Secondly, in reactor, add PRA-4, methylene dichloride, triethylamine, stirring and dissolving under the nitrogen protection again;-5 ℃～10 ℃ add dimethyl tertiary butyl chloride silane down, and the question response heat release finishes, and removes ice bath, rises to stirring at room 2 hours; Be cooled to-5 ℃～10 ℃ again, drip PRA-7/ triethylamine mixed solution, after dropwising, add Nal, rise to room temperature; Rise to 45 ℃, stirred 2 hours, after reacting completely, reduce to room temperature; With damping fluid (KH
2PO
4With Na
2HPO
4.12H
2The aqueous solution of O) pour in the reaction solution, stir 10 minutes standing demix, water layer PH=7-8 also uses methylene dichloride extracting 3 times, merges organic layer, uses the damping fluid washed twice again, and anhydrous sodium sulfate drying concentrates, and obtains oily matter; In oily matter, add acetonitrile and stir, had solid to separate out in about 5 minutes, stirred 2 hours, place 2 hours dry PRA-5B of getting of after-filtration down for 0 ℃;
Add PRA-5B at last in reactor, the THF dissolving adds triethylamine under the room temperature (25 ℃-28 ℃) again, DMAP (4-Dimethylamino pyridine), and nitrogen stirs after 15 minutes down, drips AC
2O/THF after dripping about 10 minutes, stirred 1.5 hours; Be cooled to-10 ℃, slowly drip 10mol/LKH
2PO
4Solution stirred one hour, dripped mixed solution (10mol/LKH again
2PO
4And ethanol), stirring has solid to separate out after 0.5 hour-1 hour; Filter, cold 95% washing with alcohol, placing under the room temperature and getting PRA-6B to dry weight a night is the PRA-9 prasugrel.
Embodiment one
PRA-4B
1. add tosic acid 4.77 grams in the reaction flask, 150mlTHF, stirring and dissolving;
2. add PRA-3,10 grams, interior temperature refluxed 2 hours for 64 ℃, cooling has solid filtering naturally, solid is with the THF washing of 15ml*3, weight in wet base 11.13 grams, the room temperature baking is expected to such an extent that 9.78 restrain yield 97.8%;
PRA-5B
1. add PRA-4B in the there-necked flask, 16 grams, methylene dichloride 30ml, triethylamine 7.8ml, stirring and dissolving under the nitrogen protection;
2.0 ℃ once add dimethyl tertiary butyl chloride silane 8.42ml, the question response heat release finishes, and removes ice bath, rises to stirring at room 2 hours;
3. be cooled to 0 ℃ again, (mixed solution of 11.92 grams/13.6ml) after dropwising, adds the Nal0.25 gram, rises to room temperature to drip the PRA-7/ triethylamine;
4. rise to 45 ℃, stirred 2 hours, the TLC detection reaction is complete, reduces to room temperature;
5. damping fluid 50ml is poured in the reaction solution, stir (damping fluid configuration: 9.5 gram KH in 10 minutes
2PO
4With 0.95 gram Na
2HPO
4.12H
2The about 400ml of the aqueous solution 358 grams of O);
6. layering, water layer PH=7-8,20ml*3 methylene dichloride extracting merges organic layer, and with the washing of 250ml*2 damping fluid, anhydrous sodium sulfate drying concentrates, and obtains oily matter 24.33 grams;
7. add the 50ml acetonitrile and stir, had solid to separate out in about 5 minutes, stirred 2 hours, place down for 0 ℃ and filtered in 2 hours, obtain weight in wet base 20.1 grams, dry 1.5 hours of 30 ℃ of Rotary Evaporators, constant weight 15.91 restrains yield 99.4%.
PRA-6B
1. add PRA-5B in the there-necked flask, 10g, the 30mlTHF dissolving adds triethylamine under the room temperature (25 ℃-28 ℃) again, DMAP0.287g (4-Dimethylamino pyridine), nitrogen stirs after 15 minutes down, drips AC
2O/THF (6.4ml/10ml) after dripping about 10 minutes, stirred TLC 1.5 hours;
2. be cooled to-10 ℃, slowly drip 10mol/LKH
2PO
4Solution 2ml stirred one hour, dripped mixed solution (10mol/LKH again
2PO
415ml/ ethanol 17ml), stirring has solid to separate out after 0.5 hour-1 hour;
3. filter, cold 95% ethanol 15ml*3 washing obtains weight in wet base 11.43 grams, and placing a night under the room temperature is 9.38 grams to dry weight, yield 93.8%, HPLC:99.5%, single impurity: 0.11%, 0.11486%.
Little test result: product yield is 93.8%, and quality product is 99.8%.
Embodiment two
PRA-4B
3. add tosic acid 23.85 grams in the reaction flask, 750mlTHF, stirring and dissolving;
4. add PRA-3,50 grams, interior temperature refluxed 2 hours for 64 ℃, cooling has solid filtering naturally, solid is with the THF washing of 75ml*3, weight in wet base 55.68 grams, the room temperature baking is expected to such an extent that 48.32 restrain yield 96.7%;
PRA-5B
8. add PRA-4B in the there-necked flask, 80 grams, methylene dichloride 150ml, triethylamine 39ml, stirring and dissolving under the nitrogen protection;
9.0 ℃ once add dimethyl tertiary butyl chloride silane 42.1ml, the question response heat release finishes, and removes ice bath, rises to stirring at room 2 hours;
10. be cooled to 0 ℃ again, (mixed solution of 59.6 grams/68ml) after dropwising, adds the Nal1.25 gram, rises to room temperature to drip the PRA-7/ triethylamine;
11. rise to 45 ℃, stirred 2 hours, the TLC detection reaction is complete, reduces to room temperature;
12. damping fluid 250ml is poured in the reaction solution, stirs (damping fluid configuration: 47.5 gram KH in 10 minutes
2PO
4With 4.75 gram Na
2HPO
4.12H
2The about 2000ml of the aqueous solution 1790 grams of O);
13. layering, water layer PH=7-8,100ml*3 methylene dichloride extracting merges organic layer, and with the washing of 1250ml*2 damping fluid, anhydrous sodium sulfate drying concentrates, and obtains oily matter 122.03 grams;
Stir 14. add the 250ml acetonitrile, had solid to separate out in about 5 minutes, stirred 2 hours, place down for 0 ℃ and filtered in 2 hours, obtain weight in wet base 100.8 grams, dry 1.5 hours of 30 ℃ of Rotary Evaporators, constant weight 79.43 restrains yield 99.3%.
PRA-6B
4. add PRA-5B in the there-necked flask, 50g, the 150mlTHF dissolving adds triethylamine 32 grams again under the room temperature (25 ℃-28 ℃), and DMAP1.435 restrains (4-Dimethylamino pyridine), and nitrogen stirs after 15 minutes down, drips AC
2O/THF (32ml/50ml) after dripping about 10 minutes, stirred TLC 1.5 hours;
5. be cooled to-10 ℃, slowly drip 10mol/LKH
2PO
4Solution 10ml stirred one hour, dripped mixed solution (10mol/LKH again
2PO
475ml/ ethanol 85ml), stirring has solid to separate out after 0.5 hour-1 hour;
6. filter, cold 95% ethanol 15ml*3 washing obtains weight in wet base 57.51 grams, and placing a night under the room temperature is 46.3 grams to dry weight, yield 93.8%, HPLC:99.5%, single impurity: 0.11%, 0.11486%.
Little test result: product yield is 92.6%, and quality product is 99.7%.
Embodiment three
PRA-4B
5. add tosic acid 47.7 grams in the reaction flask, 1500mlTHF, stirring and dissolving;
6. add PRA-3,100 grams, interior temperature refluxed 2 hours for 64 ℃, cooling has solid filtering naturally, solid is with the THF washing of 150ml*3, weight in wet base 112.5 grams, the room temperature baking is expected to such an extent that 98.2 restrain yield 98.2%;
PRA-5B
15. add PRA-4B in the there-necked flask, 160 grams, methylene dichloride 300ml, triethylamine 78ml, stirring and dissolving under the nitrogen protection;
16.0 ℃ once add dimethyl tertiary butyl chloride silane 84.2ml, the question response heat release finishes, and removes ice bath, rises to stirring at room 2 hours;
17. be cooled to 0 ℃ again, (mixed solution of 119.2 grams/136ml) after dropwising, adds the Nal2.5 gram, rises to room temperature to drip the PRA-7/ triethylamine;
18. rise to 45 ℃, stirred 2 hours, the TLC detection reaction is complete, reduces to room temperature;
19. damping fluid 500ml is poured in the reaction solution, stirs (damping fluid configuration: 95 gram KH in 10 minutes
2PO
4With 9.5 gram Na
2HPO
4.12H
2The about 4000ml of the aqueous solution 3580 grams of O);
20. layering, water layer PH=7-8,200ML*3 methylene dichloride extracting merges organic layer, and with the washing of 2500ml*2 damping fluid, anhydrous sodium sulfate drying concentrates, and obtains oily matter 245.3 grams;
Stir 21. add the 500ml acetonitrile, had solid to separate out in about 5 minutes, stirred 2 hours, places 0 ℃ and filtered in 2 hours, obtain weight in wet base 201.5 grams, 30 ℃ of Rotary Evaporators dryings 1.5 hours, constant weight 158.9 restrains yield 99.3%.
PRA-6B
7. add PRA-5B in the there-necked flask, 100 grams, the 300mlTHF dissolving adds triethylamine 64 grams again under the room temperature (25 ℃-28 ℃), and DMAP2.87 restrains (4-Dimethylamino pyridine), and nitrogen stirs after 15 minutes down, drips AC
20/THF (64ml/100ml) after dripping about 10 minutes, stirred TLC 1.5 hours;
8. be cooled to-10 ℃, slowly drip 10mol/LKH
2PO
4Solution 20ml stirred one hour, dripped mixed solution (10mol/LKH again
2PO
4150ml/ ethanol 170ml), stirring has solid to separate out after 0.5 hour-1 hour;
9. filter, cold 95% ethanol 15ml*3 washing obtains weight in wet base 115.1 grams, and placing a night under the room temperature is 92.9 grams to dry weight, yield 92.9%, HPLC:99.6%, single impurity: 0.11%, 0.11486%.
Little pilot-scale experiment: product yield is 92.9%, and quality product is 99.6%.
More than show and described ultimate principle of the present invention and principal character and advantage of the present invention.The technician of the industry should understand; the present invention is not restricted to the described embodiments; that describes in the foregoing description and the specification sheets just illustrates principle of the present invention; without departing from the spirit and scope of the present invention; the present invention also has various changes and modifications, and these changes and improvements all fall in the claimed scope of the invention.The claimed scope of the present invention is defined by appending claims and equivalent thereof.
Claims (3)
1. novel method of utilizing the organosilicon protective material to be prepared prasugrel is characterized in that may further comprise the steps:
A, at first make solvent at tetrahydrofuran (THF), carry out the sulfonate PRA-4B that sulfonation reaction generates corresponding ketone with tosic acid under 45 ℃～75 ℃ the condition by PRA-3 (5,6,7,7A-tetrahydrochysene-5-(trityl) thieno-[3,2-c] pyridone);
B, the PRA-4B that obtains by step a make solvent at methylene dichloride, triethylamine is done the constraint agent, generates organosilyl ketone compound PRA-5B with 2-bromo-2-(2-fluorophenyl)-1-cyclopropyl ethyl ketone (PRA-7) generation condensation reaction again under-5 ℃～10 ℃ and do constraint agent conditions such as organic bases such as triethylamine, pyridine after with dimethyl tertiary butyl chloride silane reaction the hydroxyl in the intermediate being protected under-5 ℃～10 ℃ conditions;
C, last organosilyl ketone compound PRA-5B do solvent, triethylamine or pyridine do constraint agent at tetrahydrofuran (THF), the 4-Dimethylamino pyridine is made acylation catalyst; normal temperature condition descends and aceticanhydride generation acylation reaction finally generates target product PRA-6B; PRA-9-prasugrel-the 2-[2-(acetoxyl group)-6 of reaction rules promptly commonly used preparation; the 7-dihydro-thiophene is [3,2-c] pyridines-5 (4H)-yl also]-1-cyclopropyl-2-(2-fluorophenyl) ethyl ketone.
2. according to the novel method of the described preparation prasugrel of claim 1, it is characterized in that: described PRA-3 is prepared from by following process
3. according to the novel method of the described preparation prasugrel of claim 1, it is characterized in that: described organosilicon protective material is a dimethyl tertiary butyl chloride silane.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011101577402A CN102276623A (en) | 2011-06-13 | 2011-06-13 | Novel method of preparing prasugrel with organosilicon protectant |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011101577402A CN102276623A (en) | 2011-06-13 | 2011-06-13 | Novel method of preparing prasugrel with organosilicon protectant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102276623A true CN102276623A (en) | 2011-12-14 |
Family
ID=45102406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011101577402A Pending CN102276623A (en) | 2011-06-13 | 2011-06-13 | Novel method of preparing prasugrel with organosilicon protectant |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102276623A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20121494A1 (en) * | 2012-09-07 | 2014-03-08 | Erregierre Spa | PRASUGREL CHLORIDRATE PRODUCTION PROCESS |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4740510A (en) * | 1985-01-31 | 1988-04-26 | Sanofi (S.A.) | Derivatives of alpha-(2-oxo 2,4,5,6,7,7a-hexahydro thieno[3,2-c]5-pyridyl) phenyl acetic acid, and their use as platelet and thrombotic aggregation inhibitors |
| US5874581A (en) * | 1994-10-07 | 1999-02-23 | Ube Industries, Ltd. | 2-silyloxy-tetrahydrothienopyridine, salt thereof and process for preparing the same |
| CN101472929A (en) * | 2006-04-06 | 2009-07-01 | 第一三共株式会社 | Process for producing high-purity prasugrel and acid addition salt thereof |
| WO2009098142A1 (en) * | 2008-02-06 | 2009-08-13 | Helm Ag | Prasugrel salts with improved properties |
| CN101675058A (en) * | 2007-03-02 | 2010-03-17 | 第一三共株式会社 | Process for the preparation of high-purity prasugrel hydrochloride |
| WO2011042918A2 (en) * | 2009-10-07 | 2011-04-14 | Msn Laboratories Limited | Novel and improved processes for the preparation of prasugrel, its intermediates and pharmaceutically acceptable salts |
-
2011
- 2011-06-13 CN CN2011101577402A patent/CN102276623A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4740510A (en) * | 1985-01-31 | 1988-04-26 | Sanofi (S.A.) | Derivatives of alpha-(2-oxo 2,4,5,6,7,7a-hexahydro thieno[3,2-c]5-pyridyl) phenyl acetic acid, and their use as platelet and thrombotic aggregation inhibitors |
| US5874581A (en) * | 1994-10-07 | 1999-02-23 | Ube Industries, Ltd. | 2-silyloxy-tetrahydrothienopyridine, salt thereof and process for preparing the same |
| CN101472929A (en) * | 2006-04-06 | 2009-07-01 | 第一三共株式会社 | Process for producing high-purity prasugrel and acid addition salt thereof |
| CN101675058A (en) * | 2007-03-02 | 2010-03-17 | 第一三共株式会社 | Process for the preparation of high-purity prasugrel hydrochloride |
| WO2009098142A1 (en) * | 2008-02-06 | 2009-08-13 | Helm Ag | Prasugrel salts with improved properties |
| WO2011042918A2 (en) * | 2009-10-07 | 2011-04-14 | Msn Laboratories Limited | Novel and improved processes for the preparation of prasugrel, its intermediates and pharmaceutically acceptable salts |
Non-Patent Citations (3)
| Title |
|---|
| 孙志国，等: "普拉格雷的合成", 《中国医药工业杂志》, vol. 40, no. 4, 10 April 2009 (2009-04-10) * |
| 张博宇，等: "普拉格雷类似物的合成及抗血小板聚集活性", 《中国药科大学学报》, vol. 42, no. 4, 15 August 2011 (2011-08-15) * |
| 彭锡江，等: "2- 氧代- 5, 6, 7, 7a- 四氢噻吩并[ 3, 2- c]吡啶的合成研究", 《上海应用技术学院学报（自然科学版）》, vol. 11, no. 1, 15 March 2011 (2011-03-15) * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20121494A1 (en) * | 2012-09-07 | 2014-03-08 | Erregierre Spa | PRASUGREL CHLORIDRATE PRODUCTION PROCESS |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI106126B (en) | Process for the preparation of 6-nitrogen substituted 4,5-epoxymorphinane derivatives | |
| PL93499B1 (en) | ||
| CN101497593A (en) | 5-hydroxy coumarin and pyranoid type coumarin compounds, synthesizing method and use | |
| US10947253B2 (en) | Fused polycyclic dimers | |
| CN102250101A (en) | Bis-alpha-quinoline-low molecular polyethylene glycol phthalocyanine zinc and preparation method thereof | |
| KR101050105B1 (en) | (S) - (+) - clopidogrel bisulfate | |
| CN103382195A (en) | Benzopyran chalcone compound, and preparation method and application thereof | |
| CN105130893A (en) | 1-benzyl-6-carbomethoxy methyl tetrahydroisoquinoline derivative, preparation method and application in resisting aggregation of thrombocyte | |
| CN109438448A (en) | A kind of indoles and compounds with 7-member cycle and its preparation method and application | |
| CN102276623A (en) | Novel method of preparing prasugrel with organosilicon protectant | |
| CN101486733A (en) | Oxygen-containing bridge dinuclear molybdenum cluster compound, and preparation and use thereof | |
| ES2309340T3 (en) | K CHANNEL OPENER ACTIVATED BY HIGH CONDUCTANCE CALCIUM. | |
| US20170081347A1 (en) | Functionalized azaborine compounds and azaborine-containing biarylcarboxamides, and compositions and methods thereof | |
| CN110845466B (en) | Oxycyclononadiene derivatives, pharmaceutical compositions thereof, preparation methods and uses thereof | |
| CN104341345B (en) | A kind of synthetic method of 2-methoxyl group-6-ketone-5,6,7,8-tetrahydroquinoline | |
| JP2000511897A (en) | Novel water-soluble analog of 20 (S) camptothecin | |
| CN104761567A (en) | Clopidogrel hydrogen sulfate, and intermediate and preparation method thereof | |
| CN102372707B (en) | The synthetic method of 6-methyl-4-bromo-1,6-pyrrolin [2,3-c] pyridin-7-one | |
| CN105541766B (en) | The andrographolidume derivative of a kind of sulfur-bearing, its pharmaceutical composition, synthetic method and purposes | |
| RU2686675C1 (en) | Taxane compounds and also the production method and use thereof | |
| CN102775374A (en) | Coumarin compound, and preparation method and application thereof | |
| CN102746319B (en) | A kind of preparation method of thienopyridine ketone compounds | |
| CN103265558B (en) | Prasugrel hydrobromide and pharmaceutical composition thereof and application | |
| CN101137609B (en) | Desmosdumotin, its production method and application against tumour and AIDS | |
| CN102757460B (en) | Dihydroartemisinin sesquioxide germanium compound and preparation method as well as application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20111214 |
|
| WD01 | Invention patent application deemed withdrawn after publication |